StageZero Life Sciences Ltd.

SZLSFOTCHealthcare● Active

$0.01

+$0.00(+0.00%)

Market Cap$630018

P/E Ratio—

52W High$0.03109

52W Low$0.0005

Avg Volume17

Open$0.01

Beta0.34

Free Cash Flow Financials Revenue

StageZero Life Sciences Ltd. (SZLSF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SZLSF · free cash flow · updated Jun 15, 2026

Core FCF metrics

SZLSF · FCF · TTM · margin & CAGR

Free cash flow was −$3.5M for FY2022 (fiscal year ending 2022-12-31), up 61.2% year-over-year The FCF margin was -93.0%.

FY2022 Free Cash Flow−$3.5M▲ +61.2% YoY

Trailing 12M (TTM)−$97,365trailing 4 quarters sum

FCF Margin-93.0%−$3.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SZLSF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$3.5M(0M)−$3.5M▲ +61.2%-93.0%

FY2021−$9.0M(0M)−$9.1M▼ 190.2%-179.6%

FY2020−$3.1M(0M)−$3.1M▲ +32.3%-75.5%

FY2019−$4.6M(0M)−$4.6M▼ 40.7%—

FY2018−$3.3M(0M)−$3.3M▲ +13.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SZLSF · P/FCF · FCF yield · FCF per share

StageZero Life Sciences Ltd. (SZLSF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

SZLSF · cash flow statement · operating / investing / financing

For FY2022, StageZero Life Sciences Ltd. generated −$3.5M in operating cash flow and spent 0M in capital expenditures, yielding −$3.5M in free cash flow.

Operating Activities

−$3.5M

Cash from core business operations

2022-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$1.8M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$3.5M) − |CapEx| (0M) = FCF (−$3.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SZLSF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

StageZero Life Sciences Ltd.YOU

SZLSF

−$3.5M+61.2%-93.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

StageZero Life Sciences Ltd. (SZLSF) reported free cash flow of −$3.5M for FY2022 (fiscal year ending 2022-12-31), up 61.2% year-over-year. The FCF margin was -93.0%.

StageZero Life Sciences Ltd. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SZLSF free cash flow · 8 questions

StageZero Life Sciences Ltd. free cash flow was −$3.5M for FY2022, up 61.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$97,365.

SZLSF free cash flowSZLSF FCFSZLSF FCF 2022SZLSF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · StageZero Life Sciences Ltd. · StageZero Life Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026